Synergy Pharma (SGYP) Reaches FDA Mid-Cycle Review for Plecanatide NDA; Will Continue Enrollment in Phase 3 for IBS-C
Tweet Send to a Friend
Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) today announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
